非小细胞肺癌（NSCLC）是癌症相关死亡的主要原因之一。间变性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKIs）是 EML4-ALK 阳性 NSCLC 的标准治疗方法，但对这些药物产生耐药性仍是一大挑战。本研究旨在确定对第三代 ALK-TKI 劳拉替尼（lorlatinib）获得性耐药的机制。

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

ALK inhibitors included first-generation, crizotinib; second generation, ceritinib, alectinib, and brigatinib; and third-generation, lorlatinib, with increasing capacity for ALK inhibition ...